Clinical Trials Browser

Phase 2/3 × Drug Therapy × Gynecologic × Clear all

Endometrial Neoplasms

NCT07472153 2026-03-16

PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer

Phase 2/3 Recruiting

120 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT03755739 2024-06-25

Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors

Phase 2/3 Recruiting

200 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Uterine Cervical Neoplasms, Colonic Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms

NCT04795596 2022-04-15

Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancers

Phase 2/3 Withdrawn

Gynecologic

Ovarian Neoplasms

NCT02606539 2017-03-22

SVCGTN

Phase 2/3 Unknown

20 enrolled

Gynecologic

Gestational Trophoblastic Disease

NCT00243685 2012-01-26

Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis

Phase 2/3 Completed

150 enrolled

BreastGynecologicSarcomaThoracic

Breast Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Sarcoma

Clinical Trials

RAINBO

PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer

Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors

Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancers

SVCGTN

Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis